JP2021512953A - ゲムシタビンモノホスフェートの小分子薬物コンジュゲート - Google Patents

ゲムシタビンモノホスフェートの小分子薬物コンジュゲート Download PDF

Info

Publication number
JP2021512953A
JP2021512953A JP2020564037A JP2020564037A JP2021512953A JP 2021512953 A JP2021512953 A JP 2021512953A JP 2020564037 A JP2020564037 A JP 2020564037A JP 2020564037 A JP2020564037 A JP 2020564037A JP 2021512953 A JP2021512953 A JP 2021512953A
Authority
JP
Japan
Prior art keywords
compound
int
substituted
pharmaceutically acceptable
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512953A5 (https=
JPWO2019152955A5 (https=
Inventor
スティーブン アルバート エベレット
スティーブン アルバート エベレット
クレイグ アラン コーバン
クレイグ アラン コーバン
Original Assignee
メイベリックス オンコロジー インコーポレイテッド
メイベリックス オンコロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイベリックス オンコロジー インコーポレイテッド, メイベリックス オンコロジー インコーポレイテッド filed Critical メイベリックス オンコロジー インコーポレイテッド
Publication of JP2021512953A publication Critical patent/JP2021512953A/ja
Publication of JP2021512953A5 publication Critical patent/JP2021512953A5/ja
Publication of JPWO2019152955A5 publication Critical patent/JPWO2019152955A5/ja
Priority to JP2024007282A priority Critical patent/JP2024054873A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/24—Post-translational modifications [PTMs] in chemical analysis of biological material hydroxylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020564037A 2018-02-02 2019-02-04 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート Pending JP2021512953A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007282A JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625820P 2018-02-02 2018-02-02
US62/625,820 2018-02-02
PCT/US2019/016557 WO2019152955A1 (en) 2018-02-02 2019-02-04 Small molecule drug conjugates of gemcitabine monophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007282A Division JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021512953A true JP2021512953A (ja) 2021-05-20
JP2021512953A5 JP2021512953A5 (https=) 2022-02-14
JPWO2019152955A5 JPWO2019152955A5 (https=) 2022-02-14

Family

ID=65494554

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564037A Pending JP2021512953A (ja) 2018-02-02 2019-02-04 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート
JP2024007282A Pending JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007282A Pending JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Country Status (17)

Country Link
US (1) US11760773B2 (https=)
EP (1) EP3746134A1 (https=)
JP (2) JP2021512953A (https=)
KR (1) KR20200118827A (https=)
CN (1) CN112135634A (https=)
AU (1) AU2019216531A1 (https=)
BR (1) BR112020015745A2 (https=)
CA (1) CA3091027A1 (https=)
CL (1) CL2020002022A1 (https=)
CO (1) CO2020010970A2 (https=)
EA (1) EA202091856A1 (https=)
IL (1) IL276436A (https=)
MX (1) MX2020008188A (https=)
PE (1) PE20210367A1 (https=)
PH (1) PH12020551182A1 (https=)
SG (1) SG11202007386RA (https=)
WO (1) WO2019152955A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
JP2012525364A (ja) * 2009-05-01 2012-10-22 ユニバーシティー コート オブ ジ ユニバーシティー オブ ダンディー 増殖性状態の処置または予防
US20130131008A1 (en) * 2011-10-25 2013-05-23 Board Of Regents, The University Of Texas System Lipophilic monophosphorylated derivatives and nanoparticles
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291A (zh) * 2014-04-15 2015-10-28 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU389090A1 (ru) 1971-05-17 1973-07-05 Ташкентский государственный медицинский институт Библиотека
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5229272A (en) 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
ZA859008B (en) 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
DE3786834T2 (de) 1986-04-30 1994-03-03 Otsuka Pharma Co Ltd 5-Fluoro-Uracil-Derivate.
US6702705B1 (en) 1988-05-04 2004-03-09 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
EP0418292A4 (en) 1988-05-25 1991-09-25 Research Corporation Technologies, Inc Phosphoramides useful as antitumor agents
DE3834860A1 (de) 1988-10-13 1990-04-19 Basf Ag Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE3834861A1 (de) 1988-10-13 1990-04-19 Basf Ag Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5401838A (en) 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DK0702683T3 (da) 1993-06-08 2004-02-02 Cancer Rec Tech Ltd 06-substituerede guaninderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i behandling af tumorceller
DK0795334T3 (da) 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
WO1998011484A1 (fr) 1996-09-13 1998-03-19 Hitachi, Ltd. Processeur de commande a memoire d'historique
ATE236188T1 (de) 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
NZ330360A (en) 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
TW434252B (en) 1997-07-23 2001-05-16 Univ Georgia Res Found Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine
EP1051383B1 (en) 1998-02-06 2004-07-28 De Montfort University Hydroxylation activated prodrugs
AU2531599A (en) 1998-02-12 1999-08-30 De Montfort University Hydroxylation activated drug release
DE19834751A1 (de) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
YU68102A (sh) 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
JP3692927B2 (ja) 2000-11-07 2005-09-07 日本電気株式会社 ファクシミリ装置
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
BR0207795A (pt) 2001-03-02 2004-03-23 Hoffmann La Roche Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
CN1274948C (zh) 2001-05-18 2006-09-13 赫斯工程股份有限公司 用于制造催化式排气净化器的方法和装置
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
EP1300403A1 (en) 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
EA012844B1 (ru) 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005061459A1 (en) 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same
CA2550299C (en) 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
EP3075247B1 (en) 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
GB0421294D0 (en) 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
KR100874052B1 (ko) 2004-12-17 2008-12-12 일라이 릴리 앤드 캄파니 젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2007117760A2 (en) 2006-02-06 2007-10-18 Dr. Reddy's Laboratories Ltd. Preparation of gemcitabine
US20080182816A1 (en) 2006-02-23 2008-07-31 Tam Joemy C Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
EP2136626A4 (en) 2007-03-19 2011-02-23 Oregon State Mannich base n-oxide drugs
CN100475832C (zh) 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
TWI415858B (zh) 2007-11-06 2013-11-21 Pharmaessentia Corp β－核苷之新穎合成技術
CN104955458A (zh) 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
US10000521B2 (en) * 2013-03-15 2018-06-19 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
CN105001191A (zh) * 2015-07-23 2015-10-28 广西师范学院 具有5,2’-二羟基-4’-甲氧基-3-香叶基黄酮骨架的衍生物及其制备方法和用途
US20210380626A1 (en) * 2018-02-02 2021-12-09 Maverix Oncology, Inc. Novel small molecule drug conjugates of gemcitabine derivatives
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525364A (ja) * 2009-05-01 2012-10-22 ユニバーシティー コート オブ ジ ユニバーシティー オブ ダンディー 増殖性状態の処置または予防
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
US20130131008A1 (en) * 2011-10-25 2013-05-23 Board Of Regents, The University Of Texas System Lipophilic monophosphorylated derivatives and nanoparticles
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291A (zh) * 2014-04-15 2015-10-28 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ENAKSHA WICKREMSINHE ET AL.: "Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcita", PHARMACEUTICS, vol. 5巻, JPN6023001298, 2013, pages 261 - 276, ISSN: 0004967622 *
JARKKO RAUTIO ET AL.: "Prodrugs:design and clinical applications", NATURE REVIEWS DRUG DISCOVERY, vol. 7巻, JPN6023001299, 2008, pages 255 - 270, ISSN: 0005155568 *
MORAG C.E MCFADYEN ET AL.: "Cytochrome P450 enzymes: Novel options for cancer therapeutics Mcfadyen", MOLECULAR CANCER THERAPEUTICS, vol. 3巻, JPN6023001301, 2004, pages 363 - 371, ISSN: 0004967621 *
SLUSARCZYK MAGDALENA ET AL.: "Application of Pro Tide Technology to Gemcitabine: A successful Approach to Overcome the Key Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57巻, JPN6023001300, 2014, pages 1531 - 1542, ISSN: 0004967620 *

Also Published As

Publication number Publication date
KR20200118827A (ko) 2020-10-16
PH12020551182A1 (en) 2021-05-10
US11760773B2 (en) 2023-09-19
CN112135634A (zh) 2020-12-25
MX2020008188A (es) 2020-11-18
US20210040136A1 (en) 2021-02-11
IL276436A (en) 2020-09-30
SG11202007386RA (en) 2020-08-28
WO2019152955A9 (en) 2020-08-13
EA202091856A1 (ru) 2020-12-07
BR112020015745A2 (pt) 2020-12-08
AU2019216531A1 (en) 2020-09-24
CA3091027A1 (en) 2019-08-08
PE20210367A1 (es) 2021-02-26
CO2020010970A2 (es) 2020-11-20
JP2024054873A (ja) 2024-04-17
WO2019152955A1 (en) 2019-08-08
EP3746134A1 (en) 2020-12-09
CL2020002022A1 (es) 2021-02-12

Similar Documents

Publication Publication Date Title
RU2564527C2 (ru) Производное фталазинонкетона, способ его получения и его фармацевтическое применение
JP2021512951A (ja) ゲムシタビン誘導体の新規小分子薬物コンジュゲート
US9481678B2 (en) Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors
KR101975299B1 (ko) 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도
JP2024054873A (ja) ゲムシタビンモノホスフェートの小分子薬物コンジュゲート
EP3932915A1 (en) Acryloyl-containing nuclear transport regulator and uses thereof
WO2013123745A1 (zh) 齐多夫定喹啉共轭化合物及其制备方法和抗肝癌之应用
CN103370321B (zh) 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
KR102954979B1 (ko) 아크릴-함유 핵 수출 조절제들 및 이들의 용도들
CN119874643B (zh) 一种紫杉醇前药及其制备方法和应用
US11161823B2 (en) Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof
EP4653442A1 (en) Polycyclic compound for treating neurological diseases and tumors
KR102175125B1 (ko) 미토콘드리아 표적 Hsp90 억제제 기반 화합물 및 이를 포함하는 광역학 치료를 위한 약학적 조성물
TW202527935A (zh) 吲唑巨環多晶型物
CN101305998B (zh) 芳基-3-取代羰基吡啶酮类化合物的用途
JPS61122274A (ja) 複素多環式化合物
JP2011016754A (ja) 置換フェナントレン化合物を有効成分とするがんを予防および／または治療するための医薬組成物
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230920